Drugs / WJ22096
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07253116 | Nov 2025 → Nov 2028 expected | cancer | Nanjing Jingao biomidical technology Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WJ22096 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07253116 ↗ |
| Route | Oral | “WJ22096: orally once daily after meal” NCT07253116 ↗ |